MONMOUTH JUNCTION, N.J.,
Nov. 15, 2021 /PRNewswire/ --
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment
of life-threatening conditions in the intensive care unit and
cardiac surgery using blood purification, announces its
participation in two upcoming investor conferences.
CytoSorbents will present at the Canaccord Genuity Virtual
MedTech, Diagnostics and Digital Health & Services Forum on
Thursday, November 18, 2021. Dr.
Phillip Chan, CytoSorbents' Chief
Executive Officer, will present a brief overview of the Company
operations and outlook at 11:00 a.m. Eastern
time accessible via the following Webcast Link. Company
management will also meet with investors throughout the day.
Dr. Chan will also present at the 2021 Jefferies London
Healthcare Conference. The presentation will be available
for on-demand viewing via the following Webcast Link, starting
Thursday, November 18, 2021 at
3:00 a.m. Eastern time. Management
will also hold investor meetings on Friday,
November 19, 2021.
An archived recording of CytoSorbents' presentations at both
investor conferences will be available under the Investor Relations
portion of the Company's website at Events & Presentations -
Cytosorbents, and will be available for 30 days.
About CytoSorbents Corporation (NASDAQ: CTSO)
CytoSorbents Corporation is a leader in the treatment of
life-threatening conditions in intensive care and cardiac surgery
using blood purification. Its flagship product, CytoSorb®, is
approved in the European Union with distribution in more than 70
countries around the world as an extracorporeal cytokine adsorber
designed to reduce the "cytokine storm" or "cytokine release
syndrome" seen in common critical illnesses that may result in
massive inflammation, organ failure and patient death. These are
conditions where the risk of death can be extremely high, yet few
to no effective treatments exist. CytoSorb is also being used
during and after cardiothoracic surgery to remove inflammatory
mediators that can lead to post-operative complications, including
multiple organ failure. More than 152,000 cumulative CytoSorb
devices have been utilized to date. CytoSorb was originally
introduced into the European Union under CE-Mark as a first-in-kind
cytokine adsorber. Additional CE-Mark label expansions were
received for the removal of bilirubin and myoglobin in clinical
conditions such as liver disease and trauma, respectively, and both
ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb
has also received FDA Emergency Use Authorization in the United States for use in adult critically
ill COVID-19 patients with imminent or confirmed respiratory
failure. The DrugSorb™-ATR Antithrombotic Removal System, which is
based on the same polymer technology as CytoSorb, has also been
granted FDA Breakthrough Designation for the removal of ticagrelor,
as well as FDA Breakthrough Designation for the removal of the
direct oral anticoagulant (DOAC) drugs, apixaban and rivaroxaban,
in a cardiopulmonary bypass circuit during urgent cardiothoracic
surgery. The Company is initiating two FDA approved pivotal trials
designed to support U.S. marketing approval of DrugSorb-ATR. The
first is the 120-patient, 20 center STAR-T
(Safe and Timely
Antithrombotic Removal-Ticagrelor)
randomized, controlled trial evaluating the ability of
intraoperative DrugSorb-ATR use to reduce perioperative bleeding
risk in patients on ticagrelor undergoing cardiothoracic surgery.
The second is the 120-patient, 25 center STAR–D (Safe
and Timely Antithrombotic
Removal-Direct Oral Anticoagulants) randomized,
controlled trial, evaluating the intraoperative use of DrugSorb–ATR
to reduce perioperative bleeding risk in patients undergoing
cardiothoracic surgery on direct oral anticoagulants, including
apixaban and rivaroxaban.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received non-dilutive
grant, contract, and other funding of more than $39.5 million from DARPA, the U.S. Department of
Health and Human Services (HHS), the National Institutes of Health
(NIH), National Heart, Lung, and Blood Institute (NHLBI), the U.S.
Army, the U.S. Air Force, U.S. Special Operations Command (SOCOM),
Air Force Material Command (USAF/AFMC), and others. The Company has
numerous marketed products and products under development based
upon this unique blood purification technology protected by many
issued U.S. and international patents and registered trademarks,
and multiple patent applications pending, including ECOS-300CY®,
CytoSorb-XL™, HemoDefend-RBC™, HemoDefend-BGA™, VetResQ®,
K+ontrol™, DrugSorb™, DrugSorb™-ATR, ContrastSorb, and others. For
more information, please visit the Company's websites at
www.cytosorbents.com and www.cytosorb.com or follow us
onFacebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 9, 2021, as updated
by the risks reported in our Quarterly Reports on Form 10-Q, and in
the press releases and other communications to shareholders issued
by us from time to time which attempt to advise interested parties
of the risks and factors which may affect our business. We caution
you not to place undue reliance upon any such forward-looking
statements. We undertake no obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise, other than as required
under the Federal securities laws.
Please Click to Follow Us on Facebook and Twitter
Investor Relations Contact:
Terri Anne Powers
Vice President, Investor Relations
and Corporate Communications
(732) 482-9984
tpowers@cytosorbents.com
U.S. Public Relations Contact:
Eric Kim
Rubenstein Public Relations
212-805-3052
ekim@rubensteinpr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cytosorbents-to-present-at-the-canaccord-genuity-medtech-diagnostics-and-digital-health--services-forum-and-jefferies-london-healthcare-conference-301424592.html
SOURCE CytoSorbents Corporation